Lear SEC Filings

Lear Corporation reported third‑quarter results for the period ended September 27, 2025. Net sales were $5,679.8 million, slightly above last year, while net income attributable to Lear was $108.2 million and diluted EPS was $2.02, down from $2.41. For the first nine months, sales were $17,270.5 million and diluted EPS was $6.56. Operating cash flow improved to $612.9 million year‑to‑date, supporting capital expenditures of $366.8 million, share repurchases of $150.1 million, and dividends paid of $125.4 million.

The company amended its $2.0 billion unsecured revolving credit agreement on July 24, 2025 to extend maturity to 2030, with no borrowings outstanding as of September 27, 2025. Long‑term debt, net, was $2,759.7 million, including a $100.0 million term loan at 5.223%. Year‑to‑date restructuring charges totaled $156.0 million, and Lear expects approximately $22 million of additional charges in Seating and $9 million in E‑Systems for actions initiated. The board maintained a quarterly dividend of $0.77 per share. Shares outstanding were 51,870,171 as of October 28, 2025.

Lear Corporation furnished an 8-K announcing it issued a press release reporting financial results for Q3 2025 and updating its full-year 2025 outlook. The press release is provided as Exhibit 99.1 and is incorporated by reference.

The company stated the information in Exhibit 99.1 is furnished and not deemed “filed” under the Exchange Act. Common stock trades on the NYSE under ticker LEA.

Kathleen Ligocki, a director of Lear Corporation (LEA), reported routine insider activity on 10/01/2025. She had 53 deferred stock units converted into 53 shares of common stock as the 24th quarterly installment under the Lear Outside Directors Compensation Plan per her deferral election. The Form 4 shows 3,784 shares beneficially owned following the non-derivative transaction and a total of 16,710 deferred stock units reported in derivative holdings (each unit equals one share and is payable in shares under her election). The filing was signed by an attorney-in-fact on her behalf.

Insider sale disclosed on Form 4 for LEA. Frank C. Orsini, listed as EVP and President, Seating and a director, sold 8,500 shares of Lear Corporation common stock on 08/26/2025 at a weighted average price of $110.619 per share. After the reported sale, the filing shows Orsini beneficially owned 14,785 shares. The filer notes the reported price is a weighted average from multiple trades ranging $110.335 to $110.85 and offers to provide volume-by-price details on request. The Form 4 was signed by an attorney-in-fact on 08/27/2025.

Lear Corporation (LEA) Form 144 filing summary: The filing notifies a proposed sale of 8,500 shares of common stock through Fidelity Brokerage Services LLC (900 Salem Street, Smithfield, RI) on or about 08/26/2025. The aggregate market value of the proposed sale is reported as $940,262.04 and the number of shares outstanding is listed as 53,206,093. The securities were acquired via restricted stock vesting on three dates: 1,376 shares on 01/02/2023, 6,433 shares on 02/08/2023, and 691 shares on 01/04/2024, with payment characterized as compensation. The filer reports no securities sold in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and contains the required signature and legal warnings.

Lear Corp (LEA) Form 4 filing: SVP & CFO Jason M. Cardew executed two open-market sales on 29-Jul-2025 totaling 5,000 common shares.

• Sold 3,171 shares at $99.50
• Sold 1,829 shares at $96.694

Following the transactions, Cardew directly owns 20,244 shares, down from 25,244. No derivative securities were reported and no Rule 10b5-1 plan box was checked. Estimated aggregate proceeds are roughly $0.49 million. The sale represents a modest reduction of the insider’s position while leaving a meaningful remaining stake.

Form 4 filing for Lear Corp. (LEA) discloses that President & CEO Raymond E. Scott, who is also a director, sold a total of 5,000 common shares on 29 Jul 2025.

• Weighted‐average sale prices: $96.5789 for 4,354 shares, $97.8828 for 504 shares, and $98.8444 for 142 shares (detailed price ranges provided).
• Gross proceeds ≈ $485 k.
• Following the transactions, Scott directly owns 38,729 shares, down roughly 11% from 43,729.

No derivative transactions were reported. The filing was signed by attorney-in-fact Jacqlyn Waite on 31 Jul 2025.

While the sale is modest relative to Lear’s market capitalization and Scott retains a sizable stake, investors often monitor CEO sales for potential sentiment signals.

On 24 Jul 2025 Lear Corporation (LEA) entered into a Second Amended & Restated Credit Agreement that extends the maturity of its US$2.0 billion unsecured revolving credit facility to 24 Jul 2030. JPMorgan Chase acts as administrative agent; Bank of America, BNP Paribas, Citibank and HSBC serve as syndication agents.

Borrowings will float over (i) Term Benchmark, Central Bank or Risk-Free Rates or (ii) ABR/Canadian Prime. As of 28 Jun 2025 the applicable pricing grid is 0.925%-1.450% for benchmark-based loans and 0.000%-0.450% for ABR/Prime loans. A quarterly facility fee of 0.075%-0.20% on total commitments applies.

The facility carries customary covenants, including a maximum leverage ratio, limits on fundamental changes, indebtedness and liens. Management states the company is in full covenant compliance as of the signing date. No other financial data or earnings information were provided.

Form 144 filing reports a proposed sale of 5,000 common shares on the NYSE with an aggregate market value of $492,367.64. The transaction is expected to occur on or about 29 July 2025. Relative to the 53,206,093 shares outstanding, the sale represents roughly 0.009 % of the float, indicating an immaterial level of potential selling pressure.

The securities were acquired through a series of restricted-stock vesting events between January 2020 and January 2023. No sales have been made by the filer during the past three months. By signing the notice, the filer attests to possessing no undisclosed material adverse information about the issuer.

Key details such as the seller’s identity and relationship to the issuer are not disclosed in the excerpt provided.